A RANDOMIZED TRIAL OF CLARITHROMYCIN 800 mg VERSUS 400 mg AS PART OF FIRST-LINE TRIPLE THERAPY - A RANDOMIZED TRIAL OF CLARITHROMYCIN 800 mg VERSUS 400 mg AS PART OF FIRST-LINE TRIPLE THERAPY

Start Date13 May 2017

Sponsor / Collaborator

Takamatsu Red Cross Hospital

JPRN-UMIN000018654

/ CompletedPhase 4IIT

Randomized comparative trial of vonoprazan and esomeprazole in triple therapy for the eradication of Helicobacter pylori. - Comparative trial of vonoprazan and esomeprazole for the eradication of Helicobacter pylori (VEHP trial)

Start Date08 Jun 2015

Sponsor / Collaborator

Takamatsu Red Cross Hospital

JPRN-UMIN000020904

/ CompletedPhase 3IIT

1.2L polyethylene glycol + ascorbic acid versus 2.0L polyethylene glycol-electrolyte acid for outpatient bowel preparation. - 1.2L polyethylene glycol + ascorbic acid versus 2.0L polyethylene glycol-electrolyte acid for outpatient bowel preparation.

Start Date31 Oct 2014

Sponsor / Collaborator

Takamatsu Red Cross Hospital

100 Clinical Results associated with Takamatsu Red Cross Hospital

0 Patents (Medical) associated with Takamatsu Red Cross Hospital

509

Literatures (Medical) associated with Takamatsu Red Cross Hospital

22 Apr 2025·Blood Advances

Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry

Article

Author: Ide, Makoto ; Dispenzieri, Angela ; Alapat, Daisy ; Oksenhendler, Eric ; Lim, Megan S. ; Lechowicz, Mary Jo ; Kurzrock, Razelle ; Noy, Ariela ; Fosså, Alexander ; van Rhee, Frits ; Mukherjee, Sudipto ; Brandstadter, Joshua D. ; Hoffmann, Christian ; Navarro, José-Tomás ; Chandrakasan, Shanmuganathan ; Srkalovic, Gordan ; Nasta, Sunita ; Torigian, Drew A. ; Zhang, Lu ; Pierson, Sheila K. ; Shyamsundar, Saishravan ; Wong, Raymond S. M. ; Bagg, Adam ; Chadburn, Amy ; Casper, Corey ; Bustamante, Mateo Sarmiento ; Fajgenbaum, David C. ; Streetly, Matthew

AbstractCastleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the 2 forms of CD with unknown etiology, unicentric CD (UCD), and human herpesvirus-8–negative/idiopathic multicentric CD (iMCD). Whereas UCD cases typically present with localized lymphadenopathy and mild symptoms, iMCD involves multicentric lymphadenopathy and cytokine storm–driven symptoms with 3 recognized clinical phenotypes. Increasingly, there are anecdotal reports of cases that do not fit into this framework, but these cases have not been systematically described. Herein, we use the ACCELERATE natural history registry to characterize the spectrum of CD based on disease features, symptomatology, and severity. Our results characterize a cohort of 179 CD cases, which were reviewed and confirmed by an expert panel of clinicians and hematopathologists. We show that patients with CD present on a continuous spectrum of clinical phenotypes, and we describe oligocentric CD (OligoCD), an intermediate phenotype that does not fit the criteria for UCD or iMCD. These cases tend to have “oligocentric” lymphadenopathy (median [interquartile range] regions of lymphadenopathy, 3.0 [2.0-4.0]) in a regional pattern and exhibit a mild clinical phenotype that is more similar to UCD than iMCD. We also show that patients with OligoCD are inconsistently categorized as UCD vs iMCD, highlighting the need for this characterization. Future data collected through ACCELERATE may further elucidate the natural history and risk profile of these patients.

01 Apr 2025·JCO Global Oncology

Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients

Article

Author: Sato, Sayuri ; Hoashi, Toshihiko ; Miyagawa, Takuya ; Kanazawa, Nobuo ; Uchi, Hiroshi ; Nakano, Eiji ; Nakamura, Yasuhiro ; Asagoe, Kenji ; Koizumi, Shigeru ; Kadono, Takafumi ; Iino, Shiro ; Asai, Jun ; Funakoshi, Takeru ; Nakagawa, Tomoe ; Takai, Toshihiro ; Yamamoto, Yosuke ; Hatta, Naohito ; Inozume, Takashi ; Kuwatsuka, Yutaka ; Manabe, Keiko ; Yamamoto, Yuki ; Ito, Shusaku ; Yasuda, Masahito ; Takenouchi, Tatsuya ; Doi, Reiichi ; Matsushita, Shigeto ; Yamazaki, Naoya ; Kokubu, Hiraku ; Arima, Masaru ; Maekawa, Takeo ; Hiura, Azusa ; Ito, Takamichi ; Haga, Takahiro ; Ishikawa, Masashi ; Ichigozaki, Yuki ; Fukushima, Satoshi ; Kamiya, Hideki ; Inafuku, Kazuhiro ; Minami, Shoichiro ; Kiniwa, Yukiko ; Nakagawa, Masahiro ; Ogata, Dai ; Kishi, Akiko ; Ishizuki, Shoichiro ; Iwasawa, Utsugi ; Kaneko, Takahide ; Uhara, Hisashi ; Nakama, Kenta ; Kitagawa, Hiroshi ; Umeda, Yoshiyasu

PURPOSEAdjuvant anti–PD-1 (adj PD-1) antibodies are extensively used to improve survival in patients with resected melanoma. Clinical trials on adj PD-1 antibodies have revealed significant improvements in recurrence-free survival (RFS); however, few of these trials have included patients with acral melanoma (AM).METHODSClinical data were retrospectively collected from Japanese patients who underwent resection of stage III sole AM between 2014 and 2021. Survival outcomes, including RFS, distant metastasis-free survival (DMFS), and overall survival (OS), were compared between patients without adjuvant therapy (OBS group) and those receiving adj PD-1 group.RESULTS This study included 139 patients (OBS: 79; adj PD-1: 60), with a median follow-up of 2.6 years. The baseline characteristics were comparable, except for age and nodal metastasis. No significant differences in survival were observed between the OBS and adj PD-1 groups (3-year RFS: 36.7% v 27.5%, P = .13; 3-year DMFS: 51.0% v 45.3%, P = .51; 3-year OS: 65.3% v 67.4%, P = .45). Multivariate analysis showed no survival benefit of adj PD-1 (RFS: hazard ratio [HR], 1.25, P = .29; DMFS: HR, 1.03, P = .89; and OS: HR, 0.69, P = .23). Each survival outcome after propensity score matching confirmed no significant difference between the matched OBS group (n = 52) and adj PD-1 group (n = 52; 3-year RFS: 34.3% v 25.9%, P = .22; 3-year DMFS: 45.6% v 46.5%, P = .85; 3-year OS: 60.7% v 68.9%, P = .29). CONCLUSIONAdj PD-1 did not improve the prognosis in sole AM. However, further studies are essential to evaluate the efficacy of the adj anti–PD-1 antibody in AM.

25 Mar 2025·Cureus

Fedratinib-Associated Uveitis Effectively Treated With Sub-Tenon's Triamcinolone Acetonide Injection: A Case Report

Article

Author: Saitoh, Akira ; Saitoh, Ayumi K ; Nagahara, Yukiko ; Daizumoto, Erina

This report describes the case of uveitis in a 74-year-old woman with myelofibrosis who was treated with fedratinib. Both her eyes had hyperemia, anterior chamber cells, keratic precipitates, and vitritis. Based on her clinical history, negative clinical examination findings (except for diabetes), and fedratinib treatment, she was diagnosed with fedratinib-induced uveitis. Subsequently, the patient received sub-Tenon's triamcinolone acetonide (STA) injection in both eyes. The next day, her subjective symptoms were alleviated. Moreover, her objective symptoms were deemed to have improved after the examination performed after a few days. STA injection was extremely effective for treating fedratinib-induced uveitis.

100 Deals associated with Takamatsu Red Cross Hospital

100 Translational Medicine associated with Takamatsu Red Cross Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Jan 2026

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Takamatsu Red Cross Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Jan 2026

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing